These comparative safety differences make AOD-9604 potentially suitable for individuals who might not tolerate full growth hormone therapy or who have contraindications to traditional GH use
This resource is designed to help professional researchers design their studies while furthering their understanding of the mechanisms behind 5-amino-1MQ
We proposed to continue to apply the reporting ratio, when applicable, to all HCPCS codes to which we have proposed status indicator assignments of J1, J2, P, Q1, Q2, Q3, R, S, T, V, and U (other than New Technology APCs to which we have proposed status indicator assignments of S and T)
Beneficiaries and secondary payers thereby share in the reduction of payments to these hospitals